Back to search
FDAFDA · Food and drugs·Recall number D-886-2013

Rifadin (rifampin) capsules, USP, 150 mg, 100-count capsules per bottle, Manufactured by: Fabrique par Sanofi-Aventis Canada Inc., Laval, Quebec, Canada H7L4A8, DIN # 02091887

Published August 21, 2013 · Recall initiated: February 26, 2013

Summary

FDA records drug Class II recall D-886-2013, published August 21, 2013 and initiated February 26, 2013. Recalling firm: Sanofi-Synthelabo; Status: Terminated; Reported quantity: 998 Bottles; Lot: Lot # 3099036, Exp 03/2014. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug: During review of retain samples, the manufacturer observed low fill in some capsules, which was related to an issue detected with the encapsulating equipment.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Sanofi-Synthelabo
Distributor
Canada
Lot
Lot # 3099036, Exp 03/2014
Risk classification
Class II
Area (FDA)
drug
Country
Canada

Related recalls

Questions about this recall

Was Rifadin (rifampin) capsules, USP, 150 mg, 100-count capsules per bottle, Manufactured by: Fabrique par Sanofi-Aventis Canada Inc., Laval, Quebec, Canada H7L4A8, DIN # 02091887 recalled?

Yes. FDA published recall D-886-2013 on August 21, 2013. Reported hazard: Subpotent Drug: During review of retain samples, the manufacturer observed low fill in some capsules, which was related to an issue detected with the encapsulating equipment.

What should I do if I have this product?

Voluntary: Firm initiated · Letter